We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.
The Esperanza Nacional Award for Research in Multiple Sclerosis granted by the Multiple Sclerosis Association of Toledo (ADEMTO) aims to promote and recognize the research carried out by national research groups in the field of multiple sclerosis. This year, the third edition of the award has recognized a work led by researchers from Cemcat, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute (VHIR).
The study, published in 2022 in the journal Brain, analyzes the levels of free kappa light chains in cerebrospinal fluid and concludes that their accuracy in diagnosing new cases of multiple sclerosis is slightly higher than that of oligoclonal bands, the biomarker currently included in the diagnostic criteria for the disease. "Both types of proteins are associated with inflammatory processes", explains Dr. Carmen Espejo, principal investigator at Cemcat and the Clinical Neuroimmunology group at VHIR, and first author of the study, together with Dr. Georgina Arrambide, neurologist and researcher at Cemcat and the Clinical Neuroimmunology group at VHIR.
"Our results show that determining the kappa free light chain index is a fast, cost-effective and readily available alternative when it is not possible to assess the presence of oligoclonal bands," the researcher says. "Therefore, we propose to modify the current diagnostic criteria, the McDonald 2017 criteria, so that either biomarker can be used to diagnose the disease."
Dr. Espejo collected the award on Monday, December 18 at ADEMTO headquarters in Toledo. "We are very grateful, as the award is a recognition of our research and a motivation to continue advancing in the knowledge of multiple sclerosis."
The study has proven the efficacy of a new biomarker to diagnose MS
Clinical neuroimmunology, General Hospital
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Vall d’Hebron University Hospital Foundation – Research Institute. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.